PYC Therapeutics Ltd (PYC.AX) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Australia · ISIN AU000000PYC7

Price
1.88 AUD
Market cap
1.85 bn AUD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-6.25 %
Return on assets (ROA)
-6.12 %

PYC Therapeutics Ltd financials

Fiscal year20252026
Revenue23.49 m AUD–
Gross profit23.49 m AUD-1.20 m AUD
Operating income-53.63 m AUD-82.67 m AUD
EBIT-53.63 m AUD-82.67 m AUD
Net income-50.30 m AUD-43.34 m AUD
Diluted EPS – continuing operations-0.10 AUD-0.06 AUD

Full history since 2004, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About PYC Therapeutics Ltd

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.